The collaboration marks a turning point in AI-driven drug design and trial forecasting, de-risking the drug development ...
AstraZeneca's $15 billion pledge to its China operations highlights the country's advantages. But other regions are also hoping to host more clinical studies.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results